Navigation Links
Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
Date:9/14/2011

RICHMOND, Calif., Sept. 14, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an overview of the company's business strategy at 7:30 am ET on Wednesday, September 21, 2011 at the UBS 2011 Global Life Sciences Conference which will be held in New York City.

In addition, Geoffrey Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development will review progress of Sangamo's ZFP Therapeutic® development programs, specifically data from the company's SB-728-T program for HIV/AIDS which are to be presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20, 2011 in Chicago.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
2. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
3. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
4. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
5. Sangamo Announces Pricing of Public Offering of Common Stock
6. Sangamo Announces Public Offering of Common Stock
7. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
8. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
9. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
10. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Having proven that ... South African bio-technology company, Green Cell Technologies® (GCT®), has turned its ... directly challenging current outdated ‘pressing’ methods, ushering in a new era of modern, ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... and academic medical centers. The network provides members nationally scaled infrastructure and support ... biologics and restrictive payer agreements so members can provide continuity of care for ...
(Date:8/22/2017)... ... August 22, 2017 , ... KBioBox is pleased to ... the extended GUIDE-Seq ananlysis. KBioBox has adapted their core technology and direct alignment ... with easy to understand reports, extended indel analysis, and translocation analysis. , “The ...
(Date:8/21/2017)... MI (PRWEB) , ... August 21, 2017 , ... ... Awards: Healthcare Edition 2017. The awards recognize medical centers that have implemented innovative ... their efficiency of patient care protocols, competitive advantages, financial impact/value, and market need. ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):